What the business is, and whether it's a good one at a fair price.
Develops, manufactures and sells generic pharmaceutical formulations and active pharmaceutical ingredients, with operations spanning the United States, India and emerging markets. Pharmaceuticals accounted for 99.5% of FY26 segment revenue at ₹27,812.36 crore, with the remaining 0.5% from 'Others' which posted a small operating loss. The US franchise grew around 40% year-on-year on the back of products such as Tolvaptan, Mirabegron and Risperdal Consta; the India prescription business grew 14.5% year-on-year at 1.3x IPM and emerging markets grew 49% in Q4 FY26 led by Brazil (113% in local currency). Semaglutide was launched in India under the brand Semanext, the VISUfarma acquisition added an ophthalmology franchise, and the biosimilar franchise is currently around USD 50 million. The principal cost lines are other operating expenses at 25.9% of revenue and raw materials (mainly APIs) at 16.5%, with R&D running at around 8% of sales.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from LUPIN LIMITED's filed financials and exchange disclosures
LUPIN LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LUPIN.
Yes. Over the trailing twelve months LUPIN LIMITED reported a net profit of ₹5,551 Cr on revenue of ₹29,967 Cr.
Yes. The dividend yield is 0.57% at the current price. It paid out 10% of its profit as dividend in FY26.
No. Debt stands at 0.26× equity, and it carries net debt of ₹1,742 Cr. That is lower than 35% of its 171 Pharmaceuticals peers.
On trailing P/E, LUPIN LIMITED ranks 48 of 169 in Pharmaceuticals — cheaper than 72% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session LUPIN LIMITED moves 0.72% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by LUPIN LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
